Group 1 - The core viewpoint of the article is that Yifeng Pharmacy has decided to extend the completion date of its digitalization project from July 31, 2025, to December 31, 2025, due to the complexity and interconnectivity of the systems involved [5][6]. - The total investment for the digitalization project is 80.642 million yuan, with the company planning to use the same amount from the raised funds [3]. - As of June 30, 2025, the company has invested 73.621 million yuan in the digitalization project, achieving a progress rate of 91.29% [3]. Group 2 - The delay in the project is attributed to the challenges in integrating various systems such as product, logistics, finance, and human resources, which has led to a postponement in platform integration and promotion [4]. - The company has confirmed that the extension will not change the project implementation entity, method, total investment amount, or usage of the raised funds, ensuring that it aligns with the long-term development plan and interests of shareholders [5][6]. - The board of directors and the supervisory board have approved the extension, affirming that the decision complies with relevant laws and regulations [6].

Core Viewpoint - The company intends to use its own funds to pay for part of the investment project and subsequently replace it with raised funds, which is in compliance with regulatory requirements and aims to enhance the efficiency of fund utilization [1][5]. Fundraising Basic Situation - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds, with net fundraising amounting to approximately 253.43 million yuan after deducting related expenses [1][2]. Investment Project Basic Situation - As of June 30, 2025, the total investment for the projects, including the Jiangsu Phase II, Hubei Pharmaceutical Sorting and Processing Center, and Hebei Pharmaceutical Warehouse, amounts to 253.43 million yuan, with 179.74 million yuan allocated from the raised funds [2]. Reasons for Using Own Funds - The company faces challenges in using raised funds directly for certain expenses, such as employee salaries and social insurance, which must be paid through the basic deposit account. Therefore, it plans to use up to 7.05 million yuan of its own funds for these payments and later replace them with raised funds [3][4]. Impact on the Company - The use of self-funds for project payments and subsequent replacement with raised funds is expected to improve fund utilization efficiency and ensure the smooth progress of investment projects without affecting the normal implementation of the projects [4][5]. Review Procedures and Opinions - The company's board and supervisory committee have approved the proposal to use self-funds for the investment project, confirming that this action does not harm the interests of the company or its shareholders and complies with relevant regulations [5].

Core Viewpoint - Yifeng Pharmacy has extended the completion date of its fundraising project "Yifeng Digital Platform Upgrade Project" from July 31 to December 31, 2023, due to the complexity and challenges in integrating multiple systems [1] Group 1: Project Details - The implementation subject, method, total amount of raised funds, and usage remain unchanged despite the extension of the completion date [1] - The digital project involves integrating various systems including goods, logistics, finance, and human resources, which has led to delays in platform integration and promotion [1] Group 2: Challenges and Risks - The project faces challenges due to the strong interrelation of its components and the difficulty in collaboration, which has contributed to the delay [1] - Some hardware and software systems are deeply integrated with frontline business departments, necessitating thorough testing and feedback to avoid disconnects with actual business operations [1] - Certain remaining funds for personnel salaries, social insurance, and taxes cannot be paid directly from the fundraising account and need to be temporarily covered by the company's own funds, which will later be replaced by the raised funds [1] Group 3: Strategic Adjustments - The company aims to enhance the efficiency of fund usage and reduce investment risks by carefully evaluating the current progress of the fundraising project before deciding on the extension [1]

证券日报网讯 7月30日晚间，益丰药房发布公告称，公司于2025年7月30日召开第五届董事会第十九次 会议和第五届监事会第十三次会议审议通过了《关于使用自有资金支付募投项目部分款项并以募集资金 等额置换的议案》。公司拟在"益丰数字化平台升级项目"实施期间以不超过705.00万元募集资金等额置 换自有资金先行支付的相关支出，该部分等额置换资金视同募投项目使用资金。本次募集资金等额置换 的事项无需提交股东会审议。 （编辑 任世碧） ...

Group 1 - The core point of the article is that Yifeng Pharmacy announced an extension for the completion date of its fundraising investment project, specifically the "Yifeng Digital Platform Upgrade Project," to December 31, 2025 [1] Group 2 - The fifth board meeting and the thirteenth supervisory board meeting were held on July 30, 2025, to review and approve the proposal for the extension of the fundraising investment project [1]

证券日报网讯 7月30日晚间，益丰药房发布公告称，公司第五届监事会第十三次会议审议通过了《关于 取消监事会并修订的议案》等多项议案。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 7月30日晚间，益丰药房发布公告称，公司第五届董事会第十九次会议审议通过了《关于 取消监事会并修订的议案》等多项议案。 ...

Core Viewpoint - Yifeng Pharmacy (603939) announced that it will hold the second extraordinary general meeting of shareholders on August 25, 2025, to review several proposals, including the expansion of its business scope and the cancellation of the supervisory board [1] Group 1 - The extraordinary general meeting is scheduled for August 25, 2025 [1] - The agenda includes proposals to expand the business scope and amend the company's articles of association [1] - The meeting will also address the cancellation of the supervisory board [1]

益丰药房（SH 603939，收盘价：24.22元）7月30日晚间发布公告称，公司第五届第十九次董事会会议 于2025年7月30日在湖南省长沙市金洲大道68号益丰医药物流园五楼会议室以现场加通讯方式召开。会 议审议了《关于取消监事会并修订的议案》等文件。 （文章来源：每日经济新闻） 2024年1至12月份，益丰药房的营业收入构成为：医药零售占比88.06%，医药批发占比8.76%，其他业 务占比3.19%。 ...

中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为益丰大 药房连锁股份有限公司（以下简称"益丰药房"、"公司"）向不特定对象发行 可转换公司债券的保荐人，根据《证券发行上市保荐业务管理办法》《上市公司 募集资金监管规则》《上海证券交易所股票上市规则》和《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等规定，对益丰药房拟使用自有资金支付募 投项目部分款项并以募集资金等额置换事项进行了核查，并出具核查意见如下： 一、募集资金基本情况 中信证券股份有限公司 关于益丰大药房连锁股份有限公司 使用自有资金支付募投项目部分款项并以募集资金等额置换 的核查意见 根据中国证券监督管理委员会《关于同意益丰大药房连锁股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2024〕109 号），公司 由主承销商中信证券采用余额包销方式，向社会公众公开发行可转换公司债券 1,797.4320 万张，每张面值为人民币 100.00 元，按面值发行，共计募集资金 179,743.20 万元，坐扣承销和保荐费用 1,350.00 万 ...